Nomura Asset Management Co. Ltd. acquired a new stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 14,592 shares of the exchange traded fund’s stock, valued at approximately $1,442,000.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Tidemark LLC lifted its position in shares of SPDR S&P Biotech ETF by 101.5% in the third quarter. Tidemark LLC now owns 395 shares of the exchange traded fund’s stock worth $39,000 after buying an additional 199 shares in the last quarter. ORG Partners LLC purchased a new stake in shares of SPDR S&P Biotech ETF during the 2nd quarter worth approximately $40,000. Quintet Private Bank Europe S.A. bought a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter valued at approximately $40,000. ORG Wealth Partners LLC bought a new position in shares of SPDR S&P Biotech ETF during the 3rd quarter valued at approximately $44,000. Finally, Howe & Rusling Inc. purchased a new position in shares of SPDR S&P Biotech ETF in the third quarter valued at $49,000.
SPDR S&P Biotech ETF Stock Down 0.8 %
SPDR S&P Biotech ETF stock opened at $93.40 on Friday. SPDR S&P Biotech ETF has a 52-week low of $81.14 and a 52-week high of $105.47. The company has a market cap of $7.12 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. The firm’s fifty day moving average is $98.05 and its 200 day moving average is $97.06.
About SPDR S&P Biotech ETF
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- What Are the FAANG Stocks and Are They Good Investments?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Technology Stocks Explained: Here’s What to Know About Tech
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.